Where Dicerna Pharmaceuticals Stands With Analysts
Analysts have provided the following ratings for Dicerna Pharmaceuticals (NASDAQ:DRNA) within the last quarter:
Last 30 Days
1 Month Ago
The Daily Biotech Pulse: Moderna’s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz’s Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 12)
10 Biggest Price Target Changes For Wednesday
Rosenblatt raised Coinbase Global, Inc. (NASDAQ: COIN) price target from $400 to $420. Coinbase shares rose 2.2% to $275.51 in pre-market trading.
Goldman Sachs Downgrades Dicerna Pharmaceuticals to Neutral, Lowers Price Target to $25
Goldman Sachs analyst Madhu Kumar downgrades Dicerna Pharmaceuticals (NASDAQ:DRNA) from Buy to Neutral and lowers the price target from $36 to $25.
What 10 Analyst Ratings Have To Say About Dicerna Pharmaceuticals
Analysts have provided the following ratings for Dicerna Pharmaceuticals (NASDAQ:DRNA) within the last quarter:
Last 30 Days
1 Month Ago
2 Months Ago
Chardan Capital Maintains Buy on Dicerna Pharmaceuticals, Lowers Price Target to $28
Chardan Capital analyst Keay Nakae maintains Dicerna Pharmaceuticals (NASDAQ:DRNA) with a Buy and lowers the price target from $34 to $28.
HC Wainwright & Co. Maintains Buy on Dicerna Pharmaceuticals, Lowers Price Target to $32
HC Wainwright & Co. analyst Ed Arce maintains Dicerna Pharmaceuticals (NASDAQ:DRNA) with a Buy and lowers the price target from $38 to $32.